Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
Heim, M
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. [electronic resource] - International journal of clinical pharmacology and therapeutics Dec 2003 - 616-7 p. digital
Publication Type: Journal Article
0946-1965
10.5414/cpp41616 doi
Antineoplastic Agents--pharmacology
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Benzenesulfonates--adverse effects
Carcinoma--pathology
Cell Cycle--drug effects
Colonic Neoplasms--pathology
Humans
Niacinamide--analogs & derivatives
Phenylurea Compounds
Proto-Oncogene Proteins c-raf--antagonists & inhibitors
Pyridines--adverse effects
Sorafenib
Tumor Cells, Cultured
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. [electronic resource] - International journal of clinical pharmacology and therapeutics Dec 2003 - 616-7 p. digital
Publication Type: Journal Article
0946-1965
10.5414/cpp41616 doi
Antineoplastic Agents--pharmacology
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Benzenesulfonates--adverse effects
Carcinoma--pathology
Cell Cycle--drug effects
Colonic Neoplasms--pathology
Humans
Niacinamide--analogs & derivatives
Phenylurea Compounds
Proto-Oncogene Proteins c-raf--antagonists & inhibitors
Pyridines--adverse effects
Sorafenib
Tumor Cells, Cultured